Human liver transplantation as a model to study hepatitis C virus pathogenesis

Liver Transplantation

Volumn 15, Issue 11, 2009, Pages 1395-1411

  Hughes Jr , Michael G ^a   Rosen, Hugo R ^b,c,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d Denver VA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CELL SURFACE RECEPTOR; PEGINTERFERON; RIBAVIRIN;

ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; CHIMPANZEE; DISEASE COURSE; DISEASE MODEL; EXPLANT; GRAFT INFECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INNATE IMMUNITY; LIVER BIOPSY; LIVER CANCER; LIVER TRANSPLANTATION; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS ENTRY; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER TRANSPLANTATION; VIRUS REPLICATION;

EID: 72949111133     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21866     Document Type: Review

References (150)

1. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008;14(suppl 2):S36-S44.
2. Gordon FD, Kwo P, Vargas HE. Treatment of hepatitis C in liver transplant recipients. Liver Transpl 2009;15:126-135.
3. Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl 2008;14(suppl 2):S58-S66.
4. Cohen J. Animal studies. NIH to end chimp breeding for research. Science 2007;316:1265.
5. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001;7:927-933. (Pubitemid 32756430)
6. Meuleman P, Libbrecht L, De Vos R, de Hemptinne B, Gevaert K, Vandekerckhove J, et al. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 2005;41:847-856. (Pubitemid 40462948)
7. Kneteman NM, Weiner AJ, O'Connell J, Collett M, Gao T, Aukerman L, et al. Anti-HCV therapies in chimeric SCID-Alb/uPA mice parallel outcomes in human clinical application. Hepatology 2006;43:1346-1353. (Pubitemid 43980114)
8. Kneteman NM, Howe AY, Gao T, Lewis J, Pevear D, Lund G, et al. HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology 2009;49:745-752.
9. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008;14:25-27.
10. Rosen HR. Hepatitis C virus in the human liver transplantation model. Clin Liver Dis 2003;7:107-125. (Pubitemid 36350754)
11. Bowen DG, Walker CM. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 2005;201:1709-1714.
12. Golden-Mason L, Burton JR Jr, Castelblanco N, Klarquist J, Benlloch S, Wang C, et al. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology 2006;44:1098-1109. (Pubitemid 44748361)
13. Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007;81:2545-2553. (Pubitemid 46447020)
14. Golden-Mason L, Palmer B, Klarquist J, Mengshol JA, Castelblanco N, Rosen HR. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol 2007;81:9249-9258. (Pubitemid 47311467)
15. Feld JJ, Liang TJ. Hepatitis C-identifying patients with progressive liver injury. Hepatology 2006;43(suppl 1):S194-S206. (Pubitemid 43303983)
16. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-820. (Pubitemid 26099603)
17. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999;29:250-256. (Pubitemid 29024010)
18. Roche B, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat 2007;14(suppl 1):89-96. (Pubitemid 47624117)
19. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32:673-684. (Pubitemid 30180389)
20. Arjal RR, Burton JR Jr, Villamil F, Rosen HR. Review article: the treatment of hepatitis C virus recurrence after liver transplantation. Aliment Pharmacol Ther 2007;26:127-140. (Pubitemid 46985495)
21. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210. (Pubitemid 34700779)
22. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002;51:248-252. (Pubitemid 34791456)
23. Burton JR Jr, Rosen HR. Acute rejection in HCV-infected liver transplant recipients: the great conundrum. Liver Transpl 2006;12(suppl 2):S38-S47. (Pubitemid 44742524)
24. Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997;92:1453-1457. (Pubitemid 27412863)
25. Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004;53:451-455.
26. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-1233.
27. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005;436:946-952. (Pubitemid 41191670)
28. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194:1395-1406. (Pubitemid 33081515)
29. Gordon SC, Dailey PJ, Silverman AL, Khan BA, Kodali VP, Wilber JC. Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. Hepatology 1998;28:1702-1706.
30. Terrault NA, Dailey PJ, Ferrell L, Collins ML, Wilber JC, Urdea MS, et al. Hepatitis C virus: quantitation and distribution in liver. J Med Virol 1997;51:217-224. (Pubitemid 27157804)
31. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, Batts K, Moreno-Luna L, Poterucha J, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000;32:1125-1130. (Pubitemid 30808440)
32. Morandi L, Ferrari D, Lombardo C, Pession A, Tallini G. Monitoring HCV RNA viral load by locked nucleic acid molecular beacons real time PCR. J Virol Methods 2007;140:148-154. (Pubitemid 46185604)
33. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35:680-687. (Pubitemid 34183974)
34. Baron PW, Sindram D, Higdon D, Howell DN, Gottfried MR, Tuttle-Newhall JE, et al. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl 2000;6:407-412. (Pubitemid 30489111)
35. Watt KD, Lyden ER, Gulizia JM, McCashland TM. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl 2006;12:134-139.
36. Velidedeoglu E, Mange KC, Frank A, Abt P, Desai NM, Markmann JW, et al. Factors differentially correlated with the outcome of liver transplantation in HCV+ and HCV- recipients. Transplantation 2004;77:1834-1842. (Pubitemid 38822205)
37. Vargas V, Krawczynski K, Castells L, Martinez N, Esteban J, Allende H, et al. Recurrent hepatitis C virus infection after liver transplantation: immunohistochemical assessment of the viral antigen. Liver Transpl Surg 1998;4:320-327. (Pubitemid 28323753)
38. Ballardini G, De Raffele E, Groff P, Bioulac-Sage P, Grassi A, Ghetti S, et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl 2002;8:10-20. (Pubitemid 34092667)
39. Hughes MG Jr, Chong TW, Smith RL, Evans HL, Iezzoni JC, Sawyer RG, et al. HCV infection of the transplanted liver: changing CD81 and HVR1 variants immediately after liver transplantation.AmJ Transplant 2005;5:2504-2513.
40. Hughes MG Jr, Rudy CK, Chong TW, Smith RL, Evans HL, Iezzoni JC, et al. E2 quasispecies specificity of hepatitis C virus association with allografts immediately after liver transplantation. Liver Transpl 2004;10:208-216. (Pubitemid 38240119)
41. Ohto H, Terazawa S, Sasaki N, Hino K, Ishiwata C, Kako M, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994;330:744-750.
42. Yazdanpanah Y, De Carli G, Migueres B, Lot F, Campins M, Colombo C, et al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clin Infect Dis 2005;41:1423-1430. (Pubitemid 41579983)
43. Gordon SC, Elloway RS, Long JC, Dmuchowski CF. The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology 1993;18:1338-1343.
44. Agnello V, Abel G, Knight GB, Muchmore E. Detection of widespread hepatocyte infection in chronic hepatitis C. Hepatology 1998;28:573-584. (Pubitemid 28363689)
45. Chazouilleres O, Kim M, Combs C, Ferrell L, Bacchetti P, Roberts J, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994;106:994-999. (Pubitemid 24109286)
46. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-830. (Pubitemid 28405436)
47. Pal S, Sullivan DG, Kim S, Lai KK, Kae J, Cotler SJ, et al. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology 2006;130:1107-1116.
48. Fukumoto T, Berg T, Ku Y, Bechstein WO, Knoop M, Lemmens HP, et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 1996;24:1351-1354. (Pubitemid 26399029)
49. Fong TL, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994;107:196-199. (Pubitemid 24195362)
50. Magrin S, Craxi A, Fabiano C, Simonetti RG, Fiorentino G, Marino L, et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment. Hepatology 1994;19:273-279. (Pubitemid 24978354)
51. Calleja JL, Albillos A, Cacho G, Iborra J, Abreu L, Escartin P. Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies. J Hepatol 1996;24:308-312. (Pubitemid 26106129)
52. Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;110:167-177. (Pubitemid 26021616)
53. Kakumu S, Takayanagi M, Iwata K, Okumura A, Aiyama T, Ishikawa T, et al. Cyclosporine therapy affects amino-transferase activity but not hepatitis C virus RNA levels in chronic hepatitis C. J Gastroenterol Hepatol 1997;12:62-66. (Pubitemid 27100168)
54. Negro F, Giostra E, Krawczynski K, Quadri R, Rubbia-Brandt L, Mentha G, et al. Detection of intrahepatic hepatitis C virus replication by strand-specific semi-quantitative RT-PCR: preliminary application to the liver transplantation model. J Hepatol 1998;29:1-11. (Pubitemid 28307977)
55. Powers KA, Ribeiro RM, Patel K, Pianko S, Nyberg L, Pockros P, et al. Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl 2006;12:207-216. (Pubitemid 43273778)
56. Gretch DR, Bacchi CE, Corey L, dela Rosa C, Lesniewski RR, Kowdley K, et al. Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology 1995;22:1-9.
57. Di Martino V, Saurini F, Samuel D, Gigou M, Dussaix E, Reynes M, et al. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. Hepatology 1997;26:1343-1350. (Pubitemid 27509323)
58. Duvoux C, Pawlotsky JM, Cherqui D, Tran van Nhieu J, Metreau JM, Fagniez PL, et al. Serial quantitative determination of hepatitis C virus RNA levels after liver transplantation. A useful test for diagnosis of hepatitis C virus reinfection. Transplantation 1995;60:457-461.
59. Freeman RB, Tran S, Lee YM, Rohrer RJ, Kaplan MM. Serum hepatitis C RNA titers after liver transplantation are not correlated with immunosuppression or hepatitis. Transplantation 1996;61:542-546. (Pubitemid 26073596)
60. Craggs JK, Ball JK, Thomson BJ, Irving WL, Grabowska AM. Development of a strand-specific RT-PCR based assay to detect the replicative form of hepatitis C virus RNA. J Virol Methods 2001;94:111-120.
61. Lin L, Fevery J, Hiem Yap S. A novel strand-specific RT-PCR for detection of hepatitis C virus negative-strand RNA (replicative intermediate): evidence of absence or very low level of HCV replication in peripheral blood mononuclear cells. J Virol Methods 2002;100:97-105. (Pubitemid 34003628)
62. Bartenschlager R, Pietschmann T. Efficient hepatitis C virus cell culture system: what a difference the host cell makes. Proc Natl Acad Sci U S A 2005;102:9739-9740. (Pubitemid 40993637)
63. Kimball P, Baker M, Fisher RA. Allograft TNFbeta and IL16 polymorphisms influence HCV recurrence and severity after liver transplantation. Liver Transpl 2006;12:247-252. (Pubitemid 43273783)
64. Rosen HR, Lentz JJ, Rose SL, Rabkin J, Corless CL, Taylor K, et al. Donor polymorphism of tumor necrosis factor gene: relationship with variable severity of hepatitis C recurrence after liver transplantation. Transplantation 1999;68:1898-1902. (Pubitemid 30027344)
65. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992;66:3225-3229.
66. Garcia JE, Puentes A, Suarez J, Lopez R, Vera R, Rodriguez LE, et al. Hepatitis C virus (HCV) E1 and E2 protein regions that specifically bind to HepG2 cells. J Hepatol 2002;36:254-262.
67. Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, Chin M, et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A 1996;93:1759-1763. (Pubitemid 26079830)
68. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Ohkoshi S, Shimotohno K. Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun 1991;175:220-228.
69. Kato N, Ootsuyama Y, Tanaka T, Nakagawa M, Nakazawa T, Muraiso K, et al. Marked sequence diversity in the putative envelope proteins of hepatitis C viruses. Virus Res 1992;22:107-123.
70. Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, Crawford K, et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991;180:842-848.
71. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A 1992;89:3468-3472.
72. Sullivan DG, Wilson JJ, Carithers RL Jr, Perkins JD, Gretch DR. Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns. J Virol 1998;72:10036-10043.
73. Pessoa MG, Bzowej N, Berenguer M, Phung Y, Kim M, Ferrell L, et al. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 1999;30:1513-1520.
74. Holmes EC, Moya A. Is the quasispecies concept relevant to RNA viruses? J Virol 2002;76:460-465.
75. Penin F, Combet C, Germanidis G, Frainais PO, Deleage G, Pawlotsky JM. Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 2001;75:5703-5710. (Pubitemid 32488166)
76. Basu A, Beyene A, Meyer K, Ray R. The hypervariable region 1 of the e2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system. J Virol 2004;78:4478-4486. (Pubitemid 38501067)
77. Kato N, Ikeda M, Sugiyama K, Mizutani T, Tanaka T, Shimotohno K. Hepatitis C virus population dynamics in human lymphocytes and hepatocytes infected in vitro. J Gen Virol 1998;79(pt 8):1859-1869. (Pubitemid 28392268)
78. Loriot MA, Bronowicki JP, Lagorce D, Lakehal F, Persico T, Barba G, et al. Permissiveness of human biliary epithelial cells to infection by hepatitis C virus. Hepatology 1999;29:1587-1595. (Pubitemid 29211065)
79. Rumin S, Berthillon P, Tanaka E, Kiyosawa K, Trabaud MA, Bizollon T, et al. Dynamic analysis of hepatitis C virus replication and quasispecies selection in long-term cultures of adult human hepatocytes infected in vitro. J Gen Virol 1999;80:3007-3018. (Pubitemid 29504674)
80. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 1996;93:15394-15399. (Pubitemid 27009611)
81. Shimizu YK, Igarashi H, Kiyohara T, Cabezon T, Farci P, Purcell RH, et al. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 1996;223:409-412. (Pubitemid 26319606)
82. Zhou YH, Shimizu YK, Esumi M. Monoclonal antibodies to the hypervariable region 1 of hepatitis C virus capture virus and inhibit virus adsorption to susceptible cells in vitro. Virology 2000;269:276-283. (Pubitemid 30210900)
83. Zibert A, Schreier E, Roggendorf M. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology 1995;208:653-661.
84. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 1994;91:7792-7796. (Pubitemid 24238271)
85. Gretch DR, Polyak SJ, Wilson JJ, Carithers RL Jr, Perkins JD, Corey L. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J Virol 1996;70:7622-7631. (Pubitemid 26339067)
86. Laskus T, Wang LF, Radkowski M, Vargas H, Nowicki M, Wilkinson J, et al. Exposure of hepatitis C virus (HCV) RNA-positive recipients to HCV RNA-positive blood donors results in rapid predominance of a single donor strain and exclusion and/or suppression of the recipient strain. J Virol 2001;75:2059-2066. (Pubitemid 32147545)
87. Rosen HR, Schwartz JM. Hepatitis C quasispecies and severity of recurrence: cause, consequence, or coincidence? Liver Transpl 2002;8:646-648.
88. Feray C, Shouval D, Samuel D. Will transplantation of an hepatitis C-infected graft improve the outcome of liver transplantation in HCV patients? Gastroenterology 1999;117:263-265.
89. Vargas HE, Laskus T, Wang LF, Lee R, Radkowski M, Dodson F, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology 1999;117:149-153. (Pubitemid 29297631)
90. Doughty AL, Painter DM, McCaughan GW. Post-transplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis due to hepatitis C virus. J Hepatol 2000;32:126-134.
91. Davis GL, Nelson DR, Terrault N, Pruett TL, Schiano TD, Fletcher CV, et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005;11:941-949. (Pubitemid 41122452)
92. Levy S, Todd SC, Maecker HT. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 1998;16:89-109. (Pubitemid 28183360)
93. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-941.
94. Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, et al. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 1999;73:6235-6244. (Pubitemid 29327798)
95. Forns X, Allander T, Rohwer-Nutter P, Bukh J. Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface. Virology 2000;274:75-85. (Pubitemid 30650684)
96. Patel AH, Wood J, Penin F, Dubuisson J, McKeating JA. Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J Gen Virol 2000;81(pt 12):2873-2883. (Pubitemid 32000634)
97. Roccasecca R, Ansuini H, Vitelli A, Meola A, Scarselli E, Acali S, et al. Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol 2003;77:1856-1867. (Pubitemid 36109998)
98. Koutsoudakis G, Herrmann E, Kallis S, Bartenschlager R, Pietschmann T. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J Virol 2007;81:588-598. (Pubitemid 46067886)
99. Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T, Desombere I, Reiser H, et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008;48:1761-1768.
100. Meola A, Sbardellati A, Bruni Ercole B, Cerretani M, Pezzanera M, Ceccacci A, et al. Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. J Virol 2000;74:5933-5938. (Pubitemid 30412962)
101. Takikawa S, Ishii K, Aizaki H, Suzuki T, Asakura H, Matsuura Y, et al. Cell fusion activity of hepatitis C virus envelope proteins. J Virol 2000;74:5066-5074. (Pubitemid 30313845)
102. Petracca R, Falugi F, Galli G, Norais N, Rosa D, Campagnoli S, et al. Structure-function analysis of hepatitis C virus envelope-CD81 binding. J Virol 2000;74:4824-4830. (Pubitemid 30237910)
103. Cormier EG, Tsamis F, Kajumo F, Durso RJ, Gardner JP, Dragic T. CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci U S A 2004;101:7270-7274. (Pubitemid 38638022)
104. Thomssen R, Bonk S, Thiele A. Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med Microbiol Immunol (Berl) 1993;182:329-334. (Pubitemid 24011208)
105. Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A. Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol (Berl) 1992;181:293-300.
106. Prince AM, Huima-Byron T, Parker TS, Levine DM. Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins. J Viral Hepat 1996;3:11-17. (Pubitemid 126734193)
107. Xiang J, Klinzman D, McLinden J, Schmidt WN, La- Brecque DR, Gish R, et al. Characterization of hepatitis G virus (GB-C virus) particles: evidence for a nucleocapsid and expression of sequences upstream of the E1 protein. J Virol 1998;72:2738-2744. (Pubitemid 28175509)
108. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999;96:12766-12771. (Pubitemid 29513577)
109. Monazahian M, Bohme I, Bonk S, Koch A, Scholz C, Grethe S, et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999;57:223-229. (Pubitemid 29069727)
110. Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002;76:6919-6928. (Pubitemid 41246207)
111. Wunschmann S, Medh JD, Klinzmann D, Schmidt WN, Stapleton JT. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol 2000;74:10055-10062. (Pubitemid 30780814)
112. Meyer K, Basu A, Ray R. Functional features of hepatitis C virus glycoproteins for pseudotype virus entry into mammalian cells. Virology 2000;276:214-226. (Pubitemid 30792467)
113. Wunschmann S, Muller HM, Stipp CS, Hemler ME, Stapleton JT. In vitro interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs. J Infect Dis 2006;194:1058-1067.
114. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002;21:5017-5025.
115. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007;446:801-805. (Pubitemid 46582027)
116. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 2003;278:41624-41630. (Pubitemid 37310418)
117. Kapadia SB, Barth H, Baumert T, McKeating JA, Chisari FV. Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol 2007;81:374-383. (Pubitemid 44975176)
118. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, et al. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 2005;79:8217-8229. (Pubitemid 40853525)
119. Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-Dac N. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem 2005;280:7793-7799. (Pubitemid 40349673)
120. Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, et al. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem 2006;281:18285-18295. (Pubitemid 44035485)
121. Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, et al. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol 2007;81:8063-8071. (Pubitemid 47101492)
122. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009;457:882-886.
123. Doherty DG, O'Farrelly C. Innate and adaptive lymphoid cells in the human liver. Immunol Rev 2000;174:5-20. (Pubitemid 30201375)
124. Scott-Algara D, Truong LX, Versmisse P, David A, Luong TT, Nguyen NV, et al. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol 2003;171:5663-5667. (Pubitemid 37467178)
125. Rosen HR. Transplantation immunology: what the clinician needs to know for immunotherapy. Gastroenterology 2008;134:1789-1801. (Pubitemid 351626955)
126. Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002;195:35-41. (Pubitemid 34074494)
127. Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002;195:43-49. (Pubitemid 34074495)
128. Willems B, Ede M, Marotta P, Wall W, Greg P, Lilly L, et al. Anti-HCV human immunoglobulins for the prevention of graft infection in HCV-related liver transplantation, a pilot study [abstract]. J Hepatol 2002;36:32.
129. Golden-Mason L, Rosen HR. Natural killer cells: primary target for hepatitis C virus immune evasion strategies? Liver Transpl 2006;12:363-372.
130. Meier UC, Owen RE, Taylor E, Worth A, Naoumov N, Willberg C, et al. Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J Virol 2005;79:12365-12374. (Pubitemid 41346098)
131. Nattermann J, Feldmann G, Ahlenstiel G, Langhans B, Sauerbruch T, Spengler U. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut 2006;55:869-877. (Pubitemid 43764560)
132. Rosen HR, Doherty DG, Madrigal-Estebas L, O'Farrelly C, Golden-Mason L. Pretransplantation CD56(+) innate lymphocyte populations associated with severity of hepatitis C virus recurrence. Liver Transpl 2008;14:31-40. (Pubitemid 351167986)
133. Varchetta S, Oliviero B, Francesca Donato M, Agnelli F, Rigamonti C, Paudice E, et al. Prospective study of natural killer cell phenotype in recurrent hepatitis C virus infection following liver transplantation. J Hepatol 2009;50:314-322.
134. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23:225-274.
135. Espadas de Arias A, Haworth SE, Belli LS, Burra P, Pinzello G, Vangeli M, et al. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation. Liver Transpl 2009;15:390-399.
136. Rosen HR, Hinrichs DJ, Gretch DR, Koziel MJ, Chou S, Houghton M, et al. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999;117:926-932. (Pubitemid 29468236)
137. Weston SJ, Leistikow RL, Reddy KR, Torres M, Wertheimer AM, Lewinsohn DM, et al. Reconstitution of hepatitis C virus-specific T-cell mediated immunity after liver transplantation. Hepatology 2005;41:72-81. (Pubitemid 40068845)
138. Schirren CA, Jung MC, Worzfeld T, Mamin M, Baretton G, Gerlach JT, et al. Hepatitis C virus-specific CD4+ T cell response after liver transplantation occurs early, is multispecific, compartmentalizes to the liver, and does not correlate with recurrent disease. J Infect Dis 2001;183:1187-1194. (Pubitemid 32281557)
139. Gruener NH, Jung MC, Ulsenheimer A, Gerlach JT, Zachoval R, Diepolder HM, et al. Analysis of a successful HCV-specific CD8+ T cell response in patients with recurrent HCV-infection after orthotopic liver transplantation. Liver Transpl 2004;10:1487-1496. (Pubitemid 40028381)
140. Smyk-Pearson S, Tester IA, Klarquist J, Palmer BE, Pawlotsky JM, Golden-Mason L, et al. Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J Virol 2008;82:1827-1837. (Pubitemid 351206931)
141. Rosen HR, Marousek G, Chou S. A longitudinal analysis of T-cell epitope-coding regions of hepatitis C virus after liver transplantation. Transplantation 2002;74:209-216. (Pubitemid 34810288)
142. Lopez-Labrador FX, Berenguer M, Sempere A, Prieto M, Sirera R, Gonzalez-Molina A, et al. Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen- A2 liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004;10:217-227. (Pubitemid 38240120)
143. Belli LS, Burra P, Poli F, Battista Alberti A, Silini E, Zavaglia C, et al. HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation. Gastroenterology 2006;130:695-702. (Pubitemid 43374520)
144. Rosen HR, Hinrichs DJ, Leistikow RL, Callender G, Wertheimer AM, Nishimura MI, et al. Cutting edge: identification of hepatitis C virus-specific CD8+ T cells restricted by donor HLA alleles following liver transplantation. J Immunol 2004;173:5355-5359. (Pubitemid 39392118)
145. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007;132:1979-1998. (Pubitemid 46695724)
146. Zeuzem S. Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients. J Hepatol 2008;49:157-159.
147. Fujiwara K, Kaneko S, Kakumu S, Sata M, Hige S, Tomita E, et al. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res 2007;37:701-710. (Pubitemid 47054776)
148. Takada Y, Ito T, Ueda Y, Haga H, Egawa H, Tanaka K, et al. Effects of double-filtration plasmapheresis combined with interferon plus ribavirin for recurrent hepatitis C after living donor liver transplantation. Liver Transpl 2008;14:1044-1047. (Pubitemid 352003905)
149. Taniguchi M, Furukawa H, Shimamura T, Suzuki T, Yamashita K, Ota M, et al. Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients with hepatitis C. Transplantation 2006;81:1747-1749. (Pubitemid 43948311)
150. Callender GG, Rosen HR, Roszkowski JJ, Lyons GE, Li M, Moore T, et al. Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition. Hepatology 2006;43:973-981. (Pubitemid 43724622)